July 27, 2023 09:05 AM EDT

As SQZ faced a final reckoning, a fateful board decision steered the company to a quick and brutal endgame

A decade after SQZ was birthed amid considerable enthusiasm and midwifed by one of the biggest scientific stars in Cambridge, MA, the few survivors of …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

As SQZ faced a final reckoning, a fateful board decision steered the company to a quick and brutal endgame

This article is available only to Premium subscribers

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

As SQZ faced a fi­nal reck­on­ing, a fate­ful board de­ci­sion steered the com­pa­ny to a quick and bru­tal endgame

This article is available only to Premium subscribers

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

As SQZ faced a final reckoning, a fateful board decision steered the company to a quick and brutal endgame

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life